This page contains brief information about rucaparib camsylate (Rubraca) and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Rucaparib camsylate is approved to treat:
- Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used:
- Prostate cancer that is metastatic, has a germline or somatic mutation in the BRCA1 or BRCA2 gene, and is castrate resistant (has not responded to treatments that lower testosterone levels). It is used in adults who have already been treated with antiandrogen therapy and chemotherapy that included a taxane.¹
Rucaparib camsylate is also being studied in the treatment of other types of cancer.
More About Rucaparib Camsylate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Rucaparib Camsylate - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Rucaparib Camsylate - Check for trials from NCI's list of cancer clinical trials now accepting patients.